Cimzia Market Report 2026

Cimzia Market Overview

• The Cimzia market growth in the historic period has been driven by approval of tnf inhibitors, rising autoimmune disease prevalence • Market expansion is supported by growth of biologic treatment guidelines, increasing diagnosis rates of autoimmune disorders • Growth Driver: Rising Rheumatoid Arthritis Prevalence Drives Cimzia Market Growth Globally • Market Trend: CIMZIA expansion offers innovative treatment for non-radiographic axial spondyloarthritis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cimzia Market?

Cimzia (certolizumab pegol) is a PEGylated monoclonal antibody that targets tumor necrosis factor (TNF), used to reduce inflammation and prevent immune system-related damage in certain autoimmune diseases. It is used in treating moderate to severe rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. The main types of Cimzia are biologics and biosimilars, designed to address the needs of adults and pediatric patients. Cimzia is distributed by various channels, such as hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. Its applications extend to treating conditions such as Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, active psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.

What Is The Cimzia Market Growth Forecast?

The cimzia market size is expected to see rapid growth in the next few years. It will grow to $7.94 million in 2030 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to growth of biologic treatment guidelines, increasing diagnosis rates of autoimmune disorders, expansion of biosimilar competition, rising patient preference for targeted therapies, improved reimbursement coverage. Major trends in the forecast period include growing adoption of tnf inhibitor biologics, expansion of use in multiple autoimmune diseases, shift toward long term disease control therapies, increased acceptance of self injected biologics, rising focus on patient quality of life.

Global Cimzia Market Segmentation

1) By Type: Biologics, Biosimilars 2) By Patient Demographics: Adults, Pediatrics 3) By Distribution Channels: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Pharmacies 4) By Application: Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Active Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis

What Are The Drivers Of The Cimzia Market?

The rise in the prevalence of rheumatoid arthritis is expected to propel the growth of the cimzia market going forward. Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by the immune system mistakenly attacking the body’s own joint tissues, leading to inflammation, pain, and swelling in the joints. The rise in the prevalence of rheumatoid arthritis (RA) can be attributed to an aging population, increasing genetic predisposition, environmental triggers like smoking and pollution, and heightened awareness and improved diagnosis of the disease. Cimzia contributes significantly to addressing the growing prevalence of rheumatoid arthritis by delivering targeted therapy that minimizes inflammation, eases symptoms, enhances patient well-being, and supports better disease management. For instance, in February 2024, according to the Arthritis WA, an Australia-based organization, by 2025, RA cases are expected to reach about 212,136 men and 362,137 women, and by 2040, these numbers are projected to rise to roughly 280,040 men and 479,828 women. Therefore, the increase in prevalence of rheumatoid arthritis is driving the growth of the cimzia industry. The rise in aging population is expected to drive the growth of the Cimzia market going forward. An aging population refers to a growing proportion of older individuals within a society due to increased life expectancy and declining birth rates. The aging population is increasing due to advancements in healthcare that have extended life expectancy. Cimzia is used by the aging population to help manage chronic inflammatory conditions like arthritis, reducing pain and improving mobility. For instance, in January 2024, according to the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, this age group’s proportion of the total U.S. population will grow from 17% to 23% during this period. Therefore, the rise in aging population is driving the growth of the Cimzia industry.

Key Players In The Global Cimzia Market

Major companies operating in the cimzia market are UCB SA

Global Cimzia Market Trends and Insights

Major companies operating in the Cimzia market are focusing on developing innovative treatments, such as autoimmune therapy solutions, to expand treatment options for patients with non-radiographic axial spondyloarthritis, addressing an unmet medical need in autoimmune disease management. Autoimmune therapy solutions are treatments designed to manage autoimmune diseases by restoring immune balance and tolerance, often using targeted immunotherapies and cellular therapies. For instance, in July 2024, UCB, a Belgium-based biopharmaceutical company, announced the expansion of CIMZIA (certolizumab pegol) as a treatment option for patients with non-radiographic axial spondyloarthritis (nr-axSpA). This expansion aims to provide an innovative therapy option for those who have not yet developed radiographic evidence of the disease but continue to experience symptoms. CIMZIA is the first and only biologic with FDA approval for nr-axSpA, highlighting its unique position in the autoimmune treatment landscape. The approval offers a crucial alternative to traditional therapies, helping patients who suffer from this inflammatory condition gain improved symptom management and quality of life.

Regional Insights

North America was the largest region in the cimzia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Cimzia Market?

The cimzia market consists of sales of injectable formulations, pre-filled syringes, auto-injectors, and IV infusions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cimzia Market Report 2026?

The cimzia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cimzia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.